MX2022008065A - 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos. - Google Patents

25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.

Info

Publication number
MX2022008065A
MX2022008065A MX2022008065A MX2022008065A MX2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A
Authority
MX
Mexico
Prior art keywords
methods
crystalline
25hc3s
colest
hidroxy
Prior art date
Application number
MX2022008065A
Other languages
English (en)
Inventor
Shawn Johnstone
Stephan D Parent
Jie Li
Robert Wenslow
Travis Lee Houston
Andrew Miksztal
Michael Holtz-Mulholland
Flavio Lopez
Howard Sard
Mario Gonzalez
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of MX2022008065A publication Critical patent/MX2022008065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se describen formas cristalinas y líquidas cristalinas de 25HC3S de sodio. La descripción incluye las Formas I, II, III, V, IX, XI y XIII de 25HC3S de sodio y combinaciones de los mismas. Las formas farmacéuticas de las formas, o combinaciones de las mismas, y métodos para tratar o prevenir enfermedades tales como hipercolesterolemia, hipertrigliceridemia y afecciones relacionadas con la acumulación de grasa y la inflamación (por ejemplo, enfermedad del hígado graso no alcohólico (EHGNA), esteatohepatitis no alcohólica (EHNA), hepatitis alcohólica, lesión renal aguda (IRA), psoriasis y aterosclerosis) se describen adicionalmente en el presente documento. También se proporcionan métodos para preparar 25HC3S.
MX2022008065A 2019-12-27 2020-12-23 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos. MX2022008065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962954279P 2019-12-27 2019-12-27
PCT/US2020/066947 WO2021133976A1 (en) 2019-12-27 2020-12-23 Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

Publications (1)

Publication Number Publication Date
MX2022008065A true MX2022008065A (es) 2022-07-27

Family

ID=76575692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008065A MX2022008065A (es) 2019-12-27 2020-12-23 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.

Country Status (14)

Country Link
US (1) US20230056273A1 (es)
EP (1) EP4081028A4 (es)
JP (2) JP2023508985A (es)
KR (1) KR20220119459A (es)
CN (1) CN115103591A (es)
AU (1) AU2020415462A1 (es)
BR (1) BR112022011358A2 (es)
CA (1) CA3165765A1 (es)
CL (1) CL2022001742A1 (es)
IL (1) IL294286A (es)
MX (1) MX2022008065A (es)
PH (1) PH12022551596A1 (es)
TW (1) TWI904127B (es)
WO (1) WO2021133976A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP4081028A4 (en) * 2019-12-27 2024-03-06 Durect Corporation CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHOD FOR THE PRODUCTION THEREOF
KR102745654B1 (ko) 2022-09-21 2024-12-20 현대모비스 주식회사 에어백 장치 및 그 전개 제어방법
KR20250134186A (ko) * 2022-12-23 2025-09-09 듀렉트 코퍼레이션 25-히드록시-콜레스트-5-엔-3-술페이트 콜린, 이의 제형 및 이의 제조 방법, 및 의학적 용도
AU2022491085A1 (en) * 2022-12-23 2025-08-07 Durect Corporation Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same
EP4417616A1 (en) 2023-02-14 2024-08-21 Ospedale San Raffaele S.r.l. Lxr antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB498916A (en) * 1936-04-13 1939-01-13 Parke Davis & Co Sterol derivatives and process of forming same
JPS5218700B2 (es) * 1973-02-16 1977-05-24
US4046760A (en) * 1976-07-01 1977-09-06 Merck & Co., Inc. Process for preparing 1-α-hydroxy cholesterol derivatives
GB1592170A (en) * 1977-01-07 1981-07-01 Hoffmann La Roche 1a-hydroxycholecalciferol-25-hydroxy esters and their use in radioimmunoassay
OA06115A (fr) * 1978-03-11 1981-06-30 Etat Du Procédé de réparation du dihydroxy-24,25 cholestérol .
JPH07309891A (ja) * 1994-05-17 1995-11-28 Nisshin Flour Milling Co Ltd ステロイド誘導体の製造法
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US20090143279A1 (en) * 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
PL3639828T3 (pl) * 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US20200222430A1 (en) * 2016-08-02 2020-07-16 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
EP4081028A4 (en) * 2019-12-27 2024-03-06 Durect Corporation CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHOD FOR THE PRODUCTION THEREOF
US20240425545A1 (en) * 2021-06-25 2024-12-26 Durect Corporation 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same
AU2022491085A1 (en) * 2022-12-23 2025-08-07 Durect Corporation Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same
KR20250134186A (ko) * 2022-12-23 2025-09-09 듀렉트 코퍼레이션 25-히드록시-콜레스트-5-엔-3-술페이트 콜린, 이의 제형 및 이의 제조 방법, 및 의학적 용도

Also Published As

Publication number Publication date
EP4081028A4 (en) 2024-03-06
WO2021133976A1 (en) 2021-07-01
TW202135829A (zh) 2021-10-01
CL2022001742A1 (es) 2023-03-24
EP4081028A1 (en) 2022-11-02
US20230056273A1 (en) 2023-02-23
KR20220119459A (ko) 2022-08-29
CA3165765A1 (en) 2021-07-01
AU2020415462A1 (en) 2022-06-23
IL294286A (en) 2022-08-01
JP2023508985A (ja) 2023-03-06
BR112022011358A2 (pt) 2022-08-23
PH12022551596A1 (en) 2023-11-20
TWI904127B (zh) 2025-11-11
CN115103591A (zh) 2022-09-23
JP2025121967A (ja) 2025-08-20

Similar Documents

Publication Publication Date Title
MX2022008065A (es) 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
PE20180690A1 (es) Composiciones de acido obeticolico y metodos de uso
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2022015243A (es) Antagonistas del receptor de lpa y usos de estos.
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
NZ724740A (en) Treatment of nafld and nash
EA201800367A1 (ru) Способы лечения болезни хантингтона
MX373840B (es) Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas.
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
BR112016026809A2 (pt) compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr
CU20190080A7 (es) Derivados de isoindolina útiles para tratar la esteatohepatitis no alcohólica y otras enfermedades de curación disfuncional del tejido y fibrosis
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
MX391804B (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
CL2017001545A1 (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida
CL2018000835A1 (es) Prevención, tratamiento y reversión de la enfermedad usando una cantidad terapeuticamente efectiva de ácidos grasos activados
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
MX382630B (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
EP4053092A4 (en) LIQUID HUMIC ACID EXTRACT
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
MX394475B (es) Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
AR128613A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa